Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18119719 | 0.88 | MAPT (0.67) | MAPTTSHRLMNACYP1A2MEN1 | |
| SCHEMBL8930617 | 0.84 | LMNA (0.66) | MAPTTSHRLMNACYP1A2MEN1 | |
| SCHEMBL19464662 | 0.83 | LMNA (0.65) | MAPTTSHRLMNACYP1A2MEN1 | |
| SCHEMBL31185236 | 0.81 | HTT (0.68) | LMNACYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL29279417 | 0.81 | HTT (0.68) | LMNACYP1A2MEN1KMT2AALDH1A1 | |
| Bucetin SCHEMBL25373 | 0.81 | GAA (0.73) | MAPTTSHRLMNACYP1A2MEN1 | |
| SCHEMBL10576308 | 0.80 | MAPT (0.86) | MAPTLMNACYP1A2MEN1KMT2A | |
| SCHEMBL7472046 | 0.80 | NPC1 (0.58) | MAPTTSHRLMNACYP1A2MEN1 | |
| SCHEMBL11129427 | 0.80 | MAPT (0.61) | MAPTTSHRLMNACYP1A2MEN1 | |
| SCHEMBL9979411 | 0.80 | POLB (0.69) | MAPTTSHRLMNACYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1063 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | OCULAR THERAPEUTIX INC (US) | 2023-09-14 | — | — | US | claimed |
| EP-4236943-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | Ocular Therapeutix, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116419755-A | Ophthalmic implant containing active agent | 视觉治疗股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2022093818-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | OCULAR THERAPEUTIX, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| CN-108901829-A | The measuring method of corn capillament vigor under a kind of drought stress conditions | 中国科学院东北地理与农业生态研究所 | 2018-11-30 | — | — | CN | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-15 | — | — | US | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | AMGEN INC. | 2009-12-17 | — | — | US | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| CN-1520292-A | Pharmaceutical composition | ������ҩ��ʽ���� | 2004-08-11 | — | — | CN | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1433396-A | Pharmaceutical compounds | NICOX SA (FR) | 2003-07-30 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0408496-A2 | Solid dosage form for pharmaceutical substances | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | MAPT 244/4885TSHR 4658/4885LMNA 3668/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | MAPT 953/4885TSHR 3553/4885LMNA 2379/4885 |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | NIM1K, NIT2, NCL | MAPT 244/4885TSHR 4658/4885LMNA 3668/4885 |
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | VRK1, VIPR1, AVPR1A | MAPT 4532/4885TSHR 505/4885LMNA 3829/4885 |
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | ERBB2, BTK, ERBB3 | MAPT 1356/4885TSHR 1202/4885LMNA 4759/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | MAPT 4304/4885TSHR 1947/4885LMNA 3648/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | MAPT 2192/4885TSHR 4149/4885LMNA 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.